196 related articles for article (PubMed ID: 34245041)
1. Aberrant expression of HIF3A in plasma of patients with non-small cell lung cancer and its clinical significance.
Wei L; Yuan N; Chen Y; Gong P
J Clin Lab Anal; 2021 Aug; 35(8):e23889. PubMed ID: 34245041
[TBL] [Abstract][Full Text] [Related]
2. Methylation of hypoxia-inducible factor 3 subunit alpha contributes to poor prognosis in lung adenocarcinoma.
Shi Q; Zheng X; Hu Y; Zhou Z; Fang M; Huang X
J Appl Genet; 2023 Dec; 64(4):769-777. PubMed ID: 37707680
[TBL] [Abstract][Full Text] [Related]
3. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
5. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
Yu H; Pang Z; Li G; Gu T
J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
[TBL] [Abstract][Full Text] [Related]
7. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
8. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
10. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
11. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
12. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
Gong L; Liu Q; Jia M; Sun X
Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
[TBL] [Abstract][Full Text] [Related]
13. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
[TBL] [Abstract][Full Text] [Related]
14. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
[TBL] [Abstract][Full Text] [Related]
16. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
Wei L; Sun JJ; Cui YC; Jiang SL; Wang XW; Lv LY; Xie L; Song XR
Tumour Biol; 2016 Jul; 37(7):9979-87. PubMed ID: 26819207
[TBL] [Abstract][Full Text] [Related]
17. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S
Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer.
Hetta HF; Zahran AM; El-Mahdy RI; Nabil EE; Esmaeel HM; Elkady OA; Elkady A; Mohareb DA; Mahmoud Mostafa M; John J
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1927-1933. PubMed ID: 31244320
[TBL] [Abstract][Full Text] [Related]
19. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
